VIROMED MEDICAL NA O.N. (VME) - Total Assets
Based on the latest financial reports, VIROMED MEDICAL NA O.N. (VME) holds total assets worth €13.91 Million EUR (≈ $16.27 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
VIROMED MEDICAL NA O.N. - Total Assets Trend (2022–2025)
This chart illustrates how VIROMED MEDICAL NA O.N.'s total assets have evolved over time, based on quarterly financial data. Also see market value of VIROMED MEDICAL NA O.N. for the company's overall valuation and market capitalisation.
VIROMED MEDICAL NA O.N. - Asset Composition Analysis
Current Asset Composition (December 2025)
VIROMED MEDICAL NA O.N.'s total assets of €13.91 Million consist of 40.8% current assets and 59.2% non-current assets. Review VIROMED MEDICAL NA O.N. balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 2.6% |
| Accounts Receivable | €1.12 Million | 8.0% |
| Inventory | €721.73K | 5.2% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €107.06K | 0.8% |
| Goodwill | €2.47 Million | 17.8% |
Asset Composition Trend (2022–2025)
This chart illustrates how VIROMED MEDICAL NA O.N.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See VIROMED MEDICAL NA O.N. (VME) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: VIROMED MEDICAL NA O.N.'s current assets represent 40.8% of total assets in 2025, an increase from 0.8% in 2022.
- Cash Position: Cash and equivalents constituted 2.6% of total assets in 2025, up from 0.7% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 17.0% of total assets, an increase from 0.0% in 2022.
- Asset Diversification: The largest asset category is goodwill at 17.8% of total assets.
VIROMED MEDICAL NA O.N. Competitors by Total Assets
Key competitors of VIROMED MEDICAL NA O.N. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
COCHLEAR LTD ADR 1/2/O.N.
F:OC50
|
Germany | €2.83 Billion |
|
TransMedics Group Inc
NASDAQ:TMDX
|
USA | $1.46 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.89 Billion |
|
Novocure Ltd
NASDAQ:NVCR
|
USA | $787.93 Million |
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.20 Billion |
|
Hangzhou AGS MedTech Co. Ltd. A
SHG:688581
|
China | CN¥2.70 Billion |
|
Nanjing Vishee Medical Technology Co Ltd
SHG:688580
|
China | CN¥1.79 Billion |
VIROMED MEDICAL NA O.N. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.74 | 3.27 | 3.27 |
| Quick Ratio | 2.39 | 3.14 | 3.14 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €3.61 Million | €6.47 Million | €6.47 Million |
VIROMED MEDICAL NA O.N. - Advanced Valuation Insights
This section examines the relationship between VIROMED MEDICAL NA O.N.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 15.52 |
| Latest Market Cap to Assets Ratio | 9.64 |
| Asset Growth Rate (YoY) | 3.9% |
| Total Assets | €13.91 Million |
| Market Capitalization | $134.15 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values VIROMED MEDICAL NA O.N.'s assets at a significant premium (9.64x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: VIROMED MEDICAL NA O.N.'s assets grew by 3.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for VIROMED MEDICAL NA O.N. (2022–2025)
The table below shows the annual total assets of VIROMED MEDICAL NA O.N. from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €13.91 Million ≈ $16.27 Million |
+3.85% |
| 2024-12-31 | €13.40 Million ≈ $15.66 Million |
-34.10% |
| 2023-12-31 | €20.33 Million ≈ $23.77 Million |
+0.36% |
| 2022-12-31 | €20.26 Million ≈ $23.68 Million |
-- |
About VIROMED MEDICAL NA O.N.
Viromed Medical AG engages in the development and distribution of products in diagnostics, therapeutics, and cold plasma technology. The company was formerly known as Fonterelli SPAC2 AG. Viromed Medical AG was incorporated in 2021 and is based in Pinneberg, Germany.